Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. Shenzhen Kangtai Biological Products Co., Ltd.
  6. News
  7. Summary
    300601   CNE100002Q33

SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD.

(300601)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Shenzhen Kangtai Biological Products Co., Ltd. Announces Recombinant COVID-19 Vaccine (Adenovirus Vector) Licensed for Manufacturing, Which Actively Promotes Vaccine Export and Improves Vaccine Accessibility

09/08/2021 | 11:40pm EDT

Shenzhen Kangtai Biological Products Co., Ltd. announced that the company and AstraZeneca signed the "Amendment 1 to License Agreement". In addition to authorizing BIOKANGTAI to commercialize its Recombinant COVID-19 Vaccine(Adenovirus Vector) in Chinese mainland, AstraZeneca has also authorized BIOKANGTAI to commercialize the vaccine in Pakistan and Indonesia. AstraZeneca provides the necessary support for BIOKANGTAI to obtain emergency use and marketing authorization in the licensed areas. BIOKANGTAI has also recently renewed the "Manufacturing License" to extend the scope of manufacturing at the company's Shenzhen Guangming Base: Recombinant COVID-19 Vaccine (Adenovirus Vector). Through the signing of this Amendment, BIOKANGTAI and AstraZeneca will expand the commercialization of Recombinant COVID-19 Vaccine(Adenovirus Vector) to overseas market, laying a foundation for the local registration and sales of the product. Meanwhile, BIOKANGTAI also has sufficient manufacturing capacity and conditions, and is expected to export the finished products to Indonesia, Pakistan and other countries in the future, which will ease the shortage of vaccine supply, and contribute to improving the accessibility and affordability of vaccines worldwide, especially in developing countries.


© S&P Capital IQ 2021
All news about SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD.
09/24Shenzhen Kangtai Biological Products Co., Ltd. Announces 2021 Interim Distribution Plan..
CI
09/16Shenzhen Kangtai Biological Products Co., Ltd. Approves Interim Cash Dividend for the F..
CI
09/08Shenzhen Kangtai Biological Products Co., Ltd. Announces Recombinant COVID-19 Vaccine (..
CI
08/30Shenzhen Kangtai Biological Products Co., Ltd. Proposes Cash Dividend for the First Hal..
CI
08/29Shenzhen Kangtai Biological Products Co., Ltd. Reports Earnings Results for the Half Ye..
CI
08/02Shenzhen Kangtai Biological Products Co., Ltd. Announces Philippine Food and Drug Admin..
CI
07/13SHENZHEN KANGTAI BIOLOGICAL PRODUCTS : Kangtai Biological to Issue $309 Million Renminbi-D..
MT
06/22Phase III Clinical Fieldwork of the Inactivated COVID-19 Vaccine (Vero Cells) Independe..
CI
05/31SHENZHEN KANGTAI BIOLOGICAL PRODUCTS : Kangtai Biological to List 1.3 Million Newly Unlock..
MT
05/25China's Kangtai Biological, partners agree to run Phase III trial in Chile - Xinhua
RE
More news
Financials
Sales 2021 3 260 M 510 M 510 M
Net income 2021 1 026 M 161 M 161 M
Net cash 2021 3 448 M 540 M 540 M
P/E ratio 2021 71,4x
Yield 2021 0,24%
Capitalization 76 493 M 11 965 M 11 975 M
EV / Sales 2021 22,4x
EV / Sales 2022 13,9x
Nbr of Employees 2 043
Free-Float 96,9%
Chart SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD.
Duration : Period :
Shenzhen Kangtai Biological Products Co., Ltd. Technical Analysis Chart | 300601 | CNE100002Q33 | MarketScreener
Technical analysis trends SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 111,35 CNY
Average target price 204,43 CNY
Spread / Average Target 83,6%
EPS Revisions
Managers and Directors
Wei Min Du Chairman & General Manager
Xiang Miao Chief Financial Officer & Board Secretary
Zhi Yun Lu Chairman-Supervisory Board
Xiang Ming Li Independent Director
Dong Guang Ma Independent Director
Sector and Competitors